Ozempic Hype Forces Employer Calls on Obesity Coverage
Employers are facing a big dilemma: How do they pay for the new highly effective and popular obesity medications without breaking the bank?
Read MorePrescription drugs
How Patents Help Keep Obesity Drug Prices Sky-High
A recent JAMA study sheds light on how the manufacturers of a class of popular weight-loss drugs have avoided competition from more affordable generics.
Read More
What to Expect When Medicare and Pharma Finally Negotiate Drug Prices
We explain how Medicare’s historic price negotiations with drugmakers will work, and the impact they could have.
Read More
Can Medicare Afford to Foot the Bill for New Alzheimer’s Drugs?
Recent analyses in JAMA and by the Kaiser Family Foundation raise questions about whether Medicare and its beneficiaries can afford a new wave of Alzheimer’s treatments.
Read More
Should Remote Opioid Addiction Treatment Stay in the Mix?
Two recent studies show the impact of an ongoing, COVID-era rule that let doctors treat opioid addiction entirely remotely.
Read More
Medicare Director Meena Seshamani on CMS’ New Drug Pricing Powers
Medicare director Meena Seshamani discusses her team’s sprint to put historic drug price reforms into action.
Read More
‘Three Health Policy Stories to Watch in 2023’ Transcript
In 2023 states will pursue new abortion laws, restart Medicaid eligibility checks and Medicare begins to flex its new power to negotiate drug prices.
Read More
Local Officials Grapple With How to Spend Billions in Opioid Settlement Dollars
More than $50 billion in opioid settlement dollars from drugmakers, distributors and pharmacies are starting to flow to state and local governments.
Read More